MOSCOW, Jul 26 (PRIME) -- The Healthcare Ministry has issued a permit for Russian pharmaceutical company Biocad to conduct clinical trials of its own anti-coronavirus vaccine, as seen by PRIME on Monday in the materials of the state register of permits for clinical trials.
“The goal of clinical trials is to evaluate safety and immunogenicity of the vaccine for prophylaxis of the COVID-19 coronavirus infection, the recombinant vector virus vaccine on the basis of AAV5-RBD-S,” the materials read.
The permit expires on December 31, 2026, and covers only the first and the second stage of clinical trials. The trials will be conducted by two medical institutions on 360 patients.
Biocad is developing the BCD-250 vaccine on the basis of a recombinant adeno-associated vector. Currently, no country in the world has registered a vaccine created with the technology. The rAAV-vector has no replicative activity, it is unable to reproduce in cells on its own, and it does not become part of human’s DNA, and causes no diseases.
End
|
|
